You are here
80.0% OF THOSE TREATED FREE FROM REPEAT HEART FAILURE RE-HOSPITALIZATION
Enterprise Imaging for Cardiology is a unified, care-centered and sophisticated imaging platform for cardiovascular professionals.
One heartbeat scans with the industry’s fastest rotation speed in a system that is affordable and accessible in the hospital, chest pain emergency (ED), or point-of-care setting.
SDSU researcher uncovers molecular pathway that protects the heart from damage during a heart attack.
The Cities and Communities with Heart Initiative Nashville brings the community together to stop the #1 killer of women
Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.
PRO-Kinetic Energy Cobalt Chromium (CoCr) Coronary Stent System from BIOTRONIK gained FDA approval utilizing results from the BIOHELIX-I clinical study. This stent, which has already been used to treat more than 650,000 patients worldwide, is now available in the US.
Mayo Clinic’s Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome and Children’s Hospital of Philadelphia are collaborating to delay and prevent heart failure for hypoplastic left heart syndrome, a rare and complex form of congenital heart disease in which the left side of a child's heart is severely underdeveloped.
Glytec’s solution will enable the 14-hospital health system to achieve best practice, reduce variability and standardize care for patients with diabetes.
Vascular Dynamics, Inc. today announces that the United States Food and Drug Administration (FDA) has approved the company’s application to participate in the Expedited Access Pathway (EAP) program for its MobiusHD® device for the treatment of resistant hypertension.
Geneva Health Solutions (formerly Geneva Healthcare) announced it raised $1.9 million to expand its Cardiac Remote Monitoring Solutions business to cardiology providers to help manage patients with implanted cardiac devices beyond the walls of the practice.
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Provides Improved Outcomes in Real-World Peripheral Arterial Disease Cases
SCAI Envisions Bright Future with Francesca Dea, Who Brings More Than 20 Years of Experience
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has closed its acquisition of Valtech Cardio Ltd
Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the world, affecting more than 12% of the world’s population, according to the World Health Organization.
Dr. Joseph Lamelas, an internationally recognized expert in minimally invasive heart surgery, has joined the Michael E. DeBakey Department of Surgery at Baylor College of Medicine as associate chief of cardiac surgery in the division of cardiothoracic surgery.
Building on European success, leading remote patient monitoring company expands to the USA to provide local support following substantial interest in its solutions
Medical device expert will help secure the development of the medical robotics start-up against the backdrop of robust growth in the cardiovascular market
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Marc Semigran, M.D., has joined the Company as chief medical officer. In his new position, Dr. Semigran will oversee clinical development and lead MyoKardia’s clinical trial strategy.